ライフサイエンスコーパス: mycoses

1 being occasional agents of human and animal mycoses.

2 exception of M. furfur and possibly endemic mycoses.

3 dioidomycosis and meningitis caused by other mycoses.

4 auses of pneumonia, including other invasive mycoses.

5 l therapy for patients with life-threatening mycoses.

6 f interferon-gamma immunity underlie endemic mycoses.

7 portant fungal pathogens that cause invasive mycoses.

8 ties for improving outcomes from HIV-related mycoses.

9 se of the assay in diagnosing other invasive mycoses.

10 gs used in treatment of topical and systemic mycoses.

11 e further developed for use against invasive mycoses.

12 to blastomycosis, which is similar to other mycoses and has parallels in humans.

13 lus mould infections, several of the endemic mycoses and serious Candida infections.

14 adily with the rise and fall of AIDS-related mycoses, and the change in spectrum of fatal disseminate

15 the current state of the-art in AIDS-related mycoses, and the key action points required to improve o

16 nto account when vaccines to protect against mycoses are designed.

17 Pulmonary mycoses are increasingly encountered in children with un

18 Cutaneous implantation and systemic mycoses are neglected diseases that affect millions of i

19 nclusion, fusaria associated with veterinary mycoses are phylogenetically diverse and typically can o

20 equiseti species complex (FIESC), with eight mycoses-associated species, may represent the second mos

21 dermatophytosis, pneumocystosis, and endemic mycoses can all be caused by PIDs.

22 e epidemiology and pathogenesis of pulmonary mycoses can be applied to prevent infection in many case

23 report the first two cases of invasive human mycoses caused by the phaeoid ascomycete, Chaetomium per

24 At the second EMBO Workshop on AIDS-Related Mycoses, clinicians and scientists from around the world

25 rium species associated with human or animal mycoses encountered in clinical microbiology laboratorie

26 Invasive mycoses have become important causes of morbidity and mo

27 erited human susceptibility to opportunistic mycoses have significantly expanded our understanding of

28 ith micafungin or ABLC decreased the risk of mycoses in high-risk recipients compared with that in lo

29 is causes one of the most prevalent systemic mycoses in Latin America--paracoccidioidomycosis.

30 to protect against the three major systemic mycoses in North America.

31 ryptococcosis is a significant opportunistic mycoses in organ transplant recipients.

32 fluconazole administration for prevention of mycoses in SICU patients appears to successfully decreas

33 egies for preventing and treating refractory mycoses in the future.

34 vel therapeutic strategies for opportunistic mycoses in transplant recipients.

35 us complications, such as those from endemic mycoses, in patients receiving treatment with a TNF-alph

36 Rare instances of aspergillosis and other mycoses, including agents of mucormycosis may also be tr

37 The incidence of mycoses is rising because of the HIV pandemic and becaus

38 heir effectiveness in the treatment of human mycoses is to be determined.

39 its effectiveness in the treatment of human mycoses is under evaluation in clinical trials.

40 eviews the changing epidemiology of invasive mycoses, new diagnostic methods, and recent therapeutic

41 inding of this study is that FSSC-associated mycoses of humans and other animals have origins in a br

42 an off-patent antifungal agent used to treat mycoses of skin and nails, has recently been demonstrate

43 implicated as the causative agents of human mycoses, particularly in the expanding immunocompromised

44 Invasive mycoses pose a major diagnostic and therapeutic challeng

45 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC) definition and analyzed surv

46 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (1

47 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (1

48 ion for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria.

49 sive Fungal Infections Cooperative Group and Mycoses Study Group (EORTC/MSG) criteria.

50 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions for fungal d

51 ion for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions of invasive

52 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions, and 6-week

53 Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG)-defined hematological po

54 isation for Research and Treatment of Cancer/Mycoses Study Group 2008 criteria) attributed to healthc

55 ization for Research and Treatment of Cancer/Mycoses Study Group consensus definitions, by direct det

56 ean Organization for the treatment of Cancer/Mycoses Study Group criteria as a reference standard.

57 ization for Research and Treatment of Cancer/Mycoses Study Group criteria classified these as "probab

58 for Research and Treatment in Cancer and the Mycoses Study Group criteria in a cohort study at our ce

59 nization of Research and Treatment of Cancer/Mycoses Study Group criteria modified for patients with

60 ion for Research and Treatment of Cancer and Mycoses Study Group criteria) in hemato-oncological pati

61 ion for the Research and Treatment of Cancer/Mycoses Study Group criteria, 32 patients had probable a

62 ization for Research and Treatment of Cancer/Mycoses Study Group criteria.

63 isation for Research and Treatment of Cancer/Mycoses Study Group definition criteria were applied and

64 ization for Research and Treatment of Cancer/Mycoses Study Group in 2008, we recategorized the 379 ep

65 Invasive Fungal Infections Cooperative Group/Mycoses Study Group of the National Institute of Allergy

66 ion for the Research and Treatment of Cancer/Mycoses Study Group.

67 oculation, several fungi can cause neglected mycoses such as sporotrichosis, chromoblastomycosis, myc

68 urements involving 55 patients with invasive mycoses who received recommended VRC doses.

69 The only mycoses with common central nervous system (CNS) involve

70 This review, based on the EMBO AIDS-Related Mycoses Workshop in Cape Town in July 2013, summarizes t